Compare General Dynamics Corporation (GD) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs Incyte Corporation — how do they compare? General Dynamics Corporation trades at $393.49 (market cap $106.03B), while Incyte Corporation trades at $120.45 (market cap $24.54B). The key difference: General Dynamics Corporation is far larger — about 4.3× Incyte Corporation's market cap, and General Dynamics Corporation pays a 1.62% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| GD | INCY | |
|---|---|---|
Market Cap | $106.03B | $24.54B |
Sector | Industrials | Health |
52-Week High | $395.97 | $129.93 |
52-Week Low | $312.53 | $81.61 |
Enterprise Value | $111.17B | $20.04B |
Dividend Yield | 1.62% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
